Alpine Immune Sciences, Inc. (ALPN) Q4 2022 Earnings Call Transcript

Alpine Immune Sciences, Inc. (ALPN) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET

Company Participants

Temre Johnson - SD, IR
Mitchell Gold - Executive Chairman, CEO
Stanford Peng - President, Head of R&D
Paul Rickey - CFO

Conference Call Participants

Mike Ulz - Morgan Stanley
Tara Bancroft - Cowen
Mark Breidenbach - Oppenheimer
Joe Pantginis - H.C. Wainwright

Operator

Welcome to the Alpine Immune Sciences Fourth Quarter 2022 Earnings Call. Currently, all participants are in listen-only mode. As a reminder, this event is being recorded.

I would now like to introduce Temre Johnson, Senior Director of Investor Relations and Corporate Communications at Alpine.

Ms. Johnson, I’ll now turn the call over to you.

Temre Johnson

Thank you, Carrie. Good afternoon and thank you for joining us. With me on the call today are Dr. Mitchell Gold, Executive Chairman and Chief Executive Officer; Dr. Stanford Peng, President and Head of Research and Development; and Paul Rickey, Chief Financial Officer.

Before I turn the call over to Mitch, I would like to remind you that we will be making forward-looking statements during today's call. These forward-looking statements are based on our current expectations and involve risk and uncertainties as a result and the timing of events, potential publication of clinical data and expectations regarding the sufficiency of cash and investment could differ materially from those anticipated in such forward-looking statements as a result of these risk and uncertainties. You may refer to the most recent SEC filings regarding risk factors associated with these statements.

Mitch, please go ahead.

Mitchell Gold

Thank you, Temre. Alpine is off to a strong start in 2023 driven by progress in the development of povetacicept, a potentially best-in-class dual inhibitor of BAFF and APRIL cytokines with a convenient once every four weeks simultaneous dosing regimen that we